Akagera Medicines, Inc Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

Akagera Medicines, Inc is a private biotechnology company focused on developing novel liposomal formulations of antibacterial drugs to address tuberculosis and other infectious diseases. Founded in 2018 in Kigali, Rwanda, the company is registered in Delaware and maintains laboratories in Boston and San Francisco, with a Kigali subsidiary created in 2022 to support manufacturing and future clinical trials. It is based in Boston, Massachusetts, and is majority-owned by the people of Rwanda.

Beyond antibacterial therapies, Akagera Medicines is developing vaccine candidates for Tuberculosis, Lassa Fever, HIV, RSV, and Influenza, in collaboration with the Gates Foundation, NIH VRC, CEPI, and a public pharmaceutical partner. A notable recent development is a partnership with CEPI to improve the delivery and accessibility of mRNA vaccines. The company has also developed a therapeutic candidate for MRSA.

Sign up for free to view info

Company overview Employee directory